F Gavosto
Overview
Explore the profile of F Gavosto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
188
Citations
285
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monfardini S, Tirelli U, Vaccher E, Errante D, Rezza G, Talamint R, et al.
Leuk Lymphoma
. 2016 Jul;
3(5-6):375-84.
PMID: 27467428
Fifty cases of Hodgkin's disease in intravenous drug users (IVDU) have been collected by the Italian Cooperative Group on AIDS-Related Tumors (G.I.C.A.T.). Ninety-two per cent of the patients were males;...
2.
Foa R, Fierro M, Tosti S, Meloni G, Gavosto F, Mandelli F
Leuk Lymphoma
. 2016 Jul;
1(2):113-7.
PMID: 27463816
A complete and persistent clinico-hematologic remission was obtained in an M4 acute myeloid leukemia patient after treatment with recombinant interleukin 2 (rIL2) alone. After two autologous bone-marrow transplantations and in...
3.
Aglietta M, Monzeglio C, Pasquino P, Carnino F, Stern A, Gavosto F
Cancer
. 1993 Nov;
72(10):2970-3.
PMID: 8221563
Background: Administration of granulocyte-macrophage colony stimulating factor (GM-CSF) is followed by a rapid increase in the proliferative activity of the hematopoietic precursors. Within 72 hours after its suspension, however, establishment...
4.
Foa R, Meloni G, Guarini A, Vignetti M, Marchis D, Tosti S, et al.
Recent Results Cancer Res
. 1993 Jan;
131:207-14.
PMID: 8210640
No abstract available.
5.
Foa R, Meloni G, Guarini A, Mandelli F, Gavosto F
Leukemia
. 1992 Nov;
6 Suppl 4:92-4.
PMID: 1434844
Based on pre-clinical findings and on more recent preliminary in vivo data it has been suggested that immunotherapy with Interleukin 2 (IL2) may be employed in the treatment of acute...
6.
Foa R, Meloni G, Guarini A, Vignetti M, Mandelli F, Gavosto F
Pharmacol Res
. 1992 Sep;
26 Suppl 2:82-3.
PMID: 1409333
No abstract available.
7.
Meloni G, Foa R, Tosti S, Vignetti M, Mancini F, Guarini A, et al.
Leukemia
. 1992 Aug;
6(8):780-5.
PMID: 1640729
In an attempt to prolong disease-free survival in children with acute leukemia, we tested the feasibility of interleukin-2 (IL-2) administration after an autologous bone marrow transplantation (ABMT). We report the...
8.
Foa R, Meloni G, Guarini A, Vignetti M, Marchis D, Tosti S, et al.
Leukemia
. 1992 Jan;
6 Suppl 3:115S-116S.
PMID: 1602806
In this paper we review some of the preclinical findings which have led us to believe that immunotherapy with interleukin 2 (IL2)/lymphokine activated killer (LAK) cells may be a feasible...
9.
Meloni G, Foa R, Capria S, Tosti S, Vignetti M, Gavosto F, et al.
Leukemia
. 1992 Jan;
6 Suppl 2:28-30.
PMID: 1578937
No abstract available.
10.
Gavosto F, Aglietta M, Caligaris Cappio F, Foa R, Saglio G
Ann Ital Med Int
. 1991 Oct;
6(4 Pt 2):451-9.
PMID: 1840812
Thanks to the impressive development and application of new sophisticated technologies, the last decade has offered remarkable advances in our understanding of the molecular and biological features of human neoplastic...